OncoMatch/Clinical Trials/NCT06363825
A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma
Is NCT06363825 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies camrelizumab for advanced hepatocellular carcinoma.
Treatment: camrelizumab — To evaluate the efficacy and safety of TAE+HAIC combined with camrelizumab and apatinib in the treatment of advanced liver cancer with high tumor load
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage ⅡA, ⅡB, ⅢA, ⅢB (CNLC)
CNLC was divided into stages Ⅱa-Ⅲb
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: targeted therapy
Previous use of targeted drugs, any component of PD-1 MAB or other similar tests
Cannot have received: PD-1 monoclonal antibody
Previous use of ... any component of PD-1 MAB or other similar tests
Cannot have received: systemic therapy
Have not received systematic treatment before
Cannot have received: local treatment
Exception: allowed if >1 month prior to enrollment
Received local treatment (such as surgical resection, radiation therapy, ablative therapy, interventional therapy, etc.) within the past 1 month
Lab requirements
Blood counts
Hemoglobin ≥100g/L; WBC ≥3×10^9/L; ANC ≥1.5×10^9/L; Platelet ≥50×10^9/L
Kidney function
Serum creatinine ≤1.5x ULN
Liver function
Child-Pugh classification grade A or B (5-8 points); Bilirubin <1.5x ULN; ALT and AST <5x ULN
Cardiac function
No severe cardiac failure; LVEF ≥50%; No grade II or above myocardial ischemia or infarction; No poorly controlled arrhythmias (QTc <450 ms men, <470 ms women); NYHA <III
The Child-Pugh classification of liver function is grade A or B (5-8 points); Bilirubin (BIL)<1.5 times the upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase AST<5ULN; Serum creatinine (Cr) ≤1.5ULN; Hemoglobin (HB) ≥100g/L; White blood cell count (WBC)≥3×10^9/L; Absolute neutrophil count (ANC)≥1.5×10^9/L; Platelet (PLT)≥50×10^9/L; Previous serious cardiovascular disease, including but not limited to the following diseases: Grade II or above myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including QTc interval ≥450 ms in men and ≥470 ms in women); According to NYHA criteria, patients with grade Ⅲ to Ⅳ cardiac insufficiency or left ventricular ejection fraction (LVEF) < 50% indicated by cardiac color ultrasound
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06363825 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage ⅡA or ⅡB or ⅢA or ⅢB is required.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages